Abstract: A multi-component synergistic absorbent composition includes at least one polysaccharide and at least one or more polysaccharide-based components or gelling proteins. This composition possesses synergistic effects in its capacity to absorb water, saline solutions and biological fluids, at normal pressure or under load, or to retain these fluids, or a combination of these properties.

Abstract: The composition of a dietary supplement is provided for increasing post workout recovery, increasing replenishment and regaining energy following exercise. A method for achieving the same is also provided. The present composition comprises branched chain amino acids, caffeine and a source of carbohydrates including waxy maize. The dietary supplement may further comprise one or more of Ginseng providing ginsenoside saponins, and Fenugreek seeds providing 4-Hydroxyisoleucine.

Abstract: A method for treating wounds, comprising providing a dry powder mixture, which when partially hydrated, forms a gel having an osmotic pressure sufficient to achieve and maintain antiseptic conditions in hydrated portions of the gel, the gelled portion comprising a biocompatible polymer, the dry powder being readily wettable by wound secretions; and applying the dry powder to a wound having wound secretions in sufficient excess to produce a self-adherent gel cake having a dry powder surface. The administration may be repeated by administration of the dry powder while wound healing progresses.

Abstract: A molecular complex of a high molecular weight carrier substance and of a medicinal substance. The carrier substance has functional groups whereby the carrier substance and the medicinal substance are bound non-covalently. The medicinal substance is insoluble or slightly soluble in water and the carrier substance is readily soluble in water. The carrier substance can be starch or a starch derivative and can have only one functional group for non-covalent binding of the medicinal substance in each molecule.

Abstract: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.

Abstract: A film-forming composition comprising a hydrocolloid, a plasticizer, and water is described. A process and apparatus for producing a non-gelatin film comprising a hydrocolloid, a plasticizer, and water is also disclosed. The process includes combining at least one non-gelatin hydrocolloid, water, and at least one plasticizer into a substantially homogeneous film-forming composition comprising at least about 40 percent water by weight. A substantial portion of the water is then extracted from the film-forming composition to form a dried portion having a water content of less than or equal to about 25 percent by weight. The dried portion of the film-forming composition is formed into a film. A film produced according to the process preferably has a tensile strength at rupture of at least about 0.4 N/mn2, and a percent elongation of at least about 50 percent at rupture at room temperature.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: A starch-based hydrogel for the controlled delivery of a biologically active agent is described. The hydrogel comprises a dispersed phase, and a dispersion medium consisting substantially of water. The dispersed phase includes a polymeric network comprising a hydrolyzable polymeric substance derived from starch, and a cross-linker. In various embodiments, the polymeric starch-derived network includes amylose, amylopectin, or a combination thereof, or soluble starch. The cross-linker is a molecule having at least two carboxyl moieties. The hyrogel is biocompatible and biodegradable, and suitable for loading with biologically active agents ranging from small molecule therapeutics to macromolecules such as proteins, polysaccharides and nucleic acids. Upon administration to a host animal, the hydrogel biodegrades, releasing as degradation products only naturally-occurring sugar molecules that are non-toxic and non-immunogenic to the host.

Abstract: Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to formula (IV) wherein HAS? is a residue of HAS or a derivative thereof linked to the thioester group, and AS? is a residue of the active substance or derivative thereof linked to the alpha-X beta-amino group; or a structure according to formula (V) wherein HAS? is a residue of HAS or derivative thereof linked to the alpha-X beta-amino group, and AS? is a residue of the active substance or derivative thereof linked to the thioester group, and wherein the group —(C?Y) is derived from the thioester group —(C?Y)—S—R? and the group HN—CH—CH2—X is derived from the alpha-X beta amino group.

Abstract: The present invention relates to an oil-in-water emulsion. The emulsion comprises a starch and a quaternary ammonium salt. The concentration of the quaternary ammonium salt is greater than about 0.5 percent by weight of the composition, the concentration of starch is greater than about 3 percent by weight of the composition, and the combined concentration of the quaternary ammonium salt plus the starch is greater than about 4 percent by weight of the composition. Methods of treating the skin are provided.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: The present invention provides a process for extracting sterols from a high solids, thermochemically hydrolyzed corn fiber using ethanol as the extractant. The process includes obtaining a corn fiber slurry having a moisture content from about 20 weight percent to about 50 weight percent solids (high solids content), thermochemically processing the corn fiber slurry having high solids content of 20 to 50% to produce a hydrolyzed corn fiber slurry, dewatering the hydrolyzed corn fiber slurry to achieve a residual corn fiber having a moisture content from about 30 to 80 weight percent solids, washing the residual corn fiber, dewatering the washed, hydrolyzed corn fiber slurry to achieve a residual corn fiber having a moisture content from about 30 to 80 weight percent solids, and extracting the residual corn fiber with ethanol and separating at least one sterol.

Abstract: A tissue adhesive formed by reacting an oxidized cationic polysaccharide containing aldehyde groups and amine groups with a multi-arm amine is described. The oxidized cationic polysaccharide-based polymer tissue adhesive may be useful for medical applications including wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, ophthalmic procedures, drug delivery, anti-adhesive applications and as a bulking agent to treat urinary incontinence. Additionally, due to the presence of the positively charged amine groups on the oxidized polysaccharide, the polymer tissue adhesive disclosed herein may promote wound healing and blood coagulation, and may possess antimicrobial properties.

Abstract: The invention relates to compounds, comprising a conjugate of hydroxyalkyl starch (HAS) and an active agent, whereby the hydroxyalkyl starch is either directly covalently bonded to the active agent, or by means of a linker. The invention further relates to methods for the production of a covalent HAS-active agent conjugate, whereby HAS and an active agent are reacted in a reaction medium, characterised in that the reaction medium is water or a mixture of water and an organic solvent, comprising at least 10 wt. % water.

Abstract: The present invention relates to processes for the manufacture of aminated or functionalized aminated polymers and their use in water-borne compositions. More specifically, this invention relates to personal care compositions containing aminated polymers and one or more other conditioning agents, surfactants and other active or inactive ingredients.

Abstract: A free-flowing, hydrophobic starch composition has a near-neutral dry product pH. Methods for making the hydrophobic starch composition by preparing an aqueous mixture comprising a starch, a siliconate, and an acid, where the aqueous mixture has a near-neutral pH, and drying the starch solids to obtain a hydrophobic starch. Novel fuel compositions comprise hydrophobic starch which can be used in internal combustion engines, such as diesel engines. Hydrophobic starch compositions may be used as fuels or fuel components. Novel methods of fueling and operating internal combustion engines use hydrophobic starch as fuel or fuel components.

Abstract: Cosmetic treatment processes include application of cosmetic compositions to a skin surface by spraying, such compositions including at least one filler in a physiologically acceptable medium, the at least one filler giving the composition a haze index H of 40% or more and a hemispheric transmission factor Th of 70% or more.

Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of bone injuries. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1.3)(1.6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1.3)(1.6) glucan and non-glucan components.

Abstract: A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

Abstract: The invention relates to a method for providing fragrance to a substrate, comprising the steps of: a) treating the substrate with a fragrance-containing composition; and b) treating the substrate with a fixative compound or mixture of fixative compounds selected from the group consisting of: a fructan; a starch hydrolysate having a dextrose equivalent ranging from 1 to 50; a hydrophobically modified fructan; and a hydrophobically modified starch hydrolysate, whereby step b) may be executed prior to, simultaneously with, and/or subsequent to the execution of step a). The invention further relates to fragrance-containing compositions and substrates.

Abstract: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.

Abstract: The present invention relates to a method for preparing enzymatically highly branched-amylose and amylopectin cluster. Alpha-glucanotransferase or branching enzyme hydrolyzes the linkage of the segment between amylopectin clusters in starch, producing amylopectin cluster, and simultaneously branching enzyme attaches the branched side-chain to amylose, producing branched amylose, and subsequently treating the amylopectin cluster or branched amylose with maltogenic amylase for cleaving long side chain into short side chain and for transferring glucose to the side chain, generating highly branched amylopectin cluster, highly branched amylose or branched oligosaccharide from starch effectively.

Abstract: An adhesion preventive material including a cross-linking polysaccharide derivative containing at least one active ester group introduced in a polysaccharide side chain, which is capable of reacting with an active hydrogen-containing group, and being capable of forming a crosslinked material due to covalent binding among the active ester group and an active hydrogen-containing group upon contact with water under an alkaline condition, is disclosed. The adhesion preventive material is able to reduce preparation works to be carried out while previously estimating the time of application and does not require a special device.

Abstract: The present invention relates to a composition comprising a starch or total dietary fiber which improves the cell viability, specifically, the inventive starch and total dietary fiber isolated from the extract of Gramineae plant and the components therefrom improved the cell viability when the cells were incubated under hypoxic condition, or in the presence of beta-amyloid and 6-hydroxydopamine treatment, as well as prevented and treated myocardiac infarction, cerebral infarction and vascular dementia, or alleviated memory loss, all of which were proven using rats as the respective animal models. Therefore, they can be used as therapeutics or health care food for preventing and treating ischemic diseases or degenerative brain diseases.

Abstract: This invention relates to a pectin-modified resistant starch prepared by cross-linking starch with pectin by pectinesterase reaction. Such resistant starch is low amylase digestible and thus is useful in food products, including nutritional supplements, to reduce calorie content and increase fiber content. This invention also relates to a composition containing the resistant starch and a process for the preparation of the same.

Abstract: The present invention relates to compositions for the enrichment, fortification and/or coloration of food, beverages, animal feed, cosmetics or pharmaceutical compositions comprising at least one modified starch, ?-carotene and optionally at least an adjuvant and/or an excipient, wherein a mixture of the composition with water has a color hue in the range of 48 to 60.

Abstract: A method for extending the gelation time of an oxidized polysaccharide to react with a water-dispersible, multi-arm amine to form a hydrogel is disclosed. The extension of the gelation time is accomplished by using a chemical additive. The method also extends the time for the hydrogel to become tack-free, and may also be used to decrease the degradation time of the hydrogel. The chemical additive reacts with the functional groups of the oxidized polysaccharide or the water-dispersible, multi-arm amine, thereby reducing the number of groups available for crosslinking. The use of the resulting hydrogel for medical and veterinary applications is described.

Abstract: The present invention relates to a composition comprising citrus fruit fiber having a water binding capacity of from 8 to 25 (w/w) and native starch selected from the group consisting of corn starch, rice flour, sorghum starch, tapioca starch and mixture thereof.

Abstract: A medical device for delivery of a therapeutic agent to a physiological target site includes a flexible receptacle containing said therapeutic agent, wherein at least a part of the receptacle is formed of a water-soluble or water-dispersible material. The therapeutic agent may include a haemostatic agent and the physiological target site may be a wound.

Abstract: A polymer dispersion or solution containing a hydrophobic polysaccharide, which is dispersed or dissolved in liquid phase, and plasticizer composition of the polysaccharide, whereby at least 10% by weight of the plasticizer composition is formed from alkenyl succinic anhydride. The invention also relates to the preparation of polymer dispersions and solutions and to the films and coatings produced from them. The dispersions according to the invention are stable, and coating with excellent film-forming properties can be prepared from them.

Abstract: Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal.

Abstract: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.

Abstract: A method for modifying an ePTFE surface by plasma immersion ion implantation includes the steps of providing an ePTFE material in a chamber suitable for plasma treatment; providing a continuous low energy plasma discharge onto the sample; and applying negative high voltage pulses of short duration to form a high energy ion flux from the plasma discharge to generate ions which form free radials on the surface of the ePTFE material without changing the molecular and/or physical structure below the surface to define a modified ePTFE surface. The step of applying the high voltage pulses modifies the surface of the ePTFE without destroying the node and fibril structure of the ePTFE, even when the step of applying the high voltage pulses etches and/or carburizes the surface of the ePTFE. The modified surface may have a depth of about 30 nm to about 500 nm. The ions are dosed onto the ePTFE sample at concentrations or doses from about 1013 ions/cm2 to about 1016 ions/cm2.

Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.

Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of dermal ulcers. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1,3)(1,6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1,3)(1,6) glucan and non-glucan components.

Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of connective tissue injuries. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1,3)(1,6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1,3)(1,6) glucan and non-glucan components.

Abstract: The invention relates to a method for producing starch networks. The method may include preparing a basic starch and preparing a networking starch. The method may further include manufacturing an initial product including the basic starch and the networking starch, and processing the initial product to yield the starch networks, such that the starch networks are at least partially heterocrystallized.

Abstract: Provided are methods of inducing satiety in an individual using gastric raft compositions and compositions suitable for such methods. The gastric raft compositions may comprise processed starches such as dextrins. Also described are methods of treating diseases characterised by hypoglycaemia, such as glycogen storage disease (GSD), and diabetes.

Abstract: Film with high solubility in water, comprising a starch, a cellulose and a cosmetic, aromatic, pharmaceutical and/or food substance in a quantity exceeding 10% on the total film weight.

Abstract: A physical mode of action pesticide for application on plants and in soils, and methods of manufacture and application, comprising an active ingredient in the form of a polymer in a concentration of less than 0.1% wt., a surfactant, a co-solvent and a diluent in a hydrocolloid suspension. The suspension polymer is preferably a polysaccharide having a molecular weight of 10,000 to 25,000,000, and preferably in the range of about 600,000. The pesticide preferably also includes a targeting ingredient for directing the active ingredient to a particular target.

Abstract: The present invention relates to monocotyledon plant cells and plants which are genetically modified, wherein the genetic modification consists of the introduction of an extraneous nucleic acid molecule which codes for a protein with the biological activity of an R1 protein. The present invention further relates to means and methods for the production thereof. Plant cells and plants of this type synthesise a modified starch, which is characterised in that it has an increased phosphate content and/or a modified phosphorylation pattern and/or an increased final viscosity in an RVA profile and/or a reduced peak temperature in DSC analysis and/or an increased gel strength in the texture analysis compared with starch from corresponding non-genetically modified monocotyledon plants. Therefore, the present invention also relates to the starch which is synthesised from the plant cells and plants according to the invention, and to methods of producing said starch.

Abstract: The present invention provides an enhanced gelling agent composition comprising a mixture of an anionic surfactant and a coupling agent. The invention also describes compositions in gel form comprising: (a) a solvent selected from the group consisting of polar solvents, non-polar solvents and combinations thereof; and (b) a gelling agent in an amount sufficient to impart gelation to the composition, the gelling agent being a mixture comprising an anionic surfactant and a coupling agent. The gels of the invention may be substantially anhydrous or may optionally contain water as part of the formulation.

Abstract: The present invention relates to cosmetic and/or dermatological compositions for the treatment of keratin containing substrates, comprising synergistic mixtures of modified starch polymers with defined molecular weights and cationic charges in a cosmetically acceptable medium. The synergistic mixtures of modified starches employed to manufacture compositions according to the present invention exhibit significant benefits over the existing modified starches employed according to the state-of-the-art in the treatment of keratin-containing substrates like human or animal hair, skin and nails. Another aspect of the present invention is the stabilization of the modified starch solutions used to manufacture the cosmetic and/or dermatological compositions according to the present invention against the growth of micro-organisms without traditional preservatives.

Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.

Abstract: A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

Abstract: The present invention relates to compositions and methods for preventing and treating osteochondrosis by administration of supplemental boron containing compounds to animals and humans. The supplemental boron containing compounds are provided in animal feed compositions or as supplements for animal feed. Also provided by this invention are animal feed compositions that are supplemented with boron containing compounds and which have reduced phosphorus content. The invention also provides a method for treating or preventing osteochondrosis in animals or humans by the administration of supplemental boron containing compounds. The invention also provides a method for decreasing the amount of phosphorus excreted by an animal, a method of increasing the efficiency of absorption of phosphorus by an animal, a method of reducing environmental phosphorus pollution by administering supplemental boron to the animal.

Abstract: A low-glycemic available carbohydrate composition of the invention contains the following components: (i) 5-60 wt. % of one or more monosaccharides selected from monosaccharides other than glucose and fructose, in particular galactose, ribose and mannose; (ii) 15-95 wt. % of oligosaccharides having a length of 2 to 20 anhydromonose units, at least half of which are anhydroglucose units linked by non-?-1,4 bonds; these oligosaccharides preferably comprising disaccharides such as palatinose, isomaltose and trehalose and/or non-?-1,4 linked higher glucose-containing oligosaccharides; (iii) 0-45 wt. % of other available carbohydrates, such as glucose and maltodextrins. This carbohydrate composition can be part of a foodcomposition for the treatment of diabetes, obesitas, insulin resistance, or for postprandial glucose response.

Abstract: A physical mode of action pesticide for application on plants and in soils, and methods of manufacture and application, comprising an active ingredient in the form of a polymer in a concentration of less than 0.1% wt., a surfactant, a co-solvent and a diluent in a hydrocolloid suspension. The suspension polymer is preferably a polysaccharide having a molecular weight of 10,000 to 25,000,000, and preferably in the range of about 600,000. The pesticide preferably also includes a targeting ingredient for directing the active ingredient to a particular target.

Abstract: The use of chemically modified dicarboxy polysaccharides for the topical treatment of the eyeball are described. The modified polysaccharides provide a carrier in solutions for the treatment of the eyeball to obtain a timed release.

Abstract: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and ?-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.